AEON Biopharma to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024
AEON Biopharma (NYSE: AEON), a clinical-stage biopharmaceutical company developing a botulinum toxin complex for multiple therapeutic indications, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference in New York, NY. The event is scheduled for September 11, 2024.
Key points:
- Marc Forth, AEON's President and CEO, will present a corporate overview at 1:30 PM ET
- One-on-one meetings with institutional investors will be available
- A live webcast of the conference event will be accessible through the conference host
This participation provides AEON an opportunity to showcase its progress and engage with potential investors, potentially impacting its market position and future funding prospects.
AEON Biopharma (NYSE: AEON), un'azienda biofarmaceutica in fase clinica che sviluppa un complesso di tossina botulinica per molteplici indicazioni terapeutiche, ha annunciato la sua partecipazione al 26掳 Convegno Annuale Global Investment di H.C. Wainwright a New York, NY. L'evento 猫 programmato per il 11 settembre 2024.
Punti chiave:
- Marc Forth, Presidente e CEO di AEON, presenter脿 una panoramica aziendale alle 13:30 ET
- Incontri individuali con investitori istituzionali saranno disponibili
- Una diretta web del convegno sar脿 accessibile tramite l'organizzatore dell'evento
Questa partecipazione offre ad AEON l'opportunit脿 di mostrare i propri progressi e interagire con potenziali investitori, influenzando potenzialmente la sua posizione di mercato e le prospettive di finanziamento future.
AEON Biopharma (NYSE: AEON), una compa帽铆a biofarmac茅utica en etapa cl铆nica que desarrolla un complejo de toxina botul铆nica para m煤ltiples indicaciones terap茅uticas, ha anunciado su participaci贸n en el 26掳 Conferencia Anual Global de Inversiones de H.C. Wainwright en Nueva York, NY. El evento est谩 programado para el 11 de septiembre de 2024.
Puntos clave:
- Marc Forth, Presidente y CEO de AEON, presentar谩 una visi贸n general de la empresa a la 1:30 PM ET
- Se ofrecer谩n reuniones individuales con inversionistas institucionales
- Una transmisi贸n en vivo del evento de la conferencia ser谩 accesible a trav茅s del anfitri贸n de la conferencia
Esta participaci贸n brinda a AEON la oportunidad de mostrar sus avances e interaccionar con potenciales inversionistas, lo que podr铆a influir en su posici贸n en el mercado y en las perspectivas de financiamiento futuro.
AEON Biopharma (NYSE: AEON)鞚� 鞐煬 旃橂 鞝侅潙歃濎潉 鞙勴暅 氤错埓毽垊鞀� 霃呾唽 氤淀暕觳措ゼ 臧滊皽頃橂姅 鞛勳儊 雼硠鞚� 氚旍澊鞓� 鞝滌暯 須岇偓搿�, 雺挫殨鞐愳劀 鞐措Μ電� H.C. Wainwright 鞝�26須� 鞐半 旮�搿滊矊 韴瀽 須岇潣鞐� 彀胳棳頃滊嫟瓿� 氚滍憸頄堨姷雼堧嫟. 鞚� 頄夓偓電� 2024雲� 9鞗� 11鞚�搿� 鞓堨爼霅橃柎 鞛堨姷雼堧嫟.
欤检殧 靷暛:
- AEON鞚� 靷灔 瓴� CEO鞚� Marc Forth臧� 鞓ろ泟 1鞁� 30攵�(ET)鞐� 須岇偓 臧滌殧毳� 氚滍憸頃╇媹雼�
- 旮瓣磤 韴瀽鞛愳檧鞚� 鞚茧寑鞚� 氙疙寘鞚� 鞝滉车霅� 鞓堨爼鞛呺媹雼�
- 須岇潣 鞚措菠韸胳潣 靸濎瓿勲姅 須岇潣 欤检禍鞛愲ゼ 韱淀暣 鞝戧芳頃� 靾� 鞛堨姷雼堧嫟
鞚措矆 彀胳棳電� AEON鞚� 鞛愳嫚鞚� 氚滌爠 靸來櫓鞚� 鞎岆Μ瓿� 鞛犾灛鞝� 韴瀽鞛愳檧 甑愲頃� 旮绊殞毳� 鞝滉车頃橃棳, 鞁滌灔 歆�鞙勳檧 頄ロ泟 鞛愱笀 臁半嫭 臧�電レ劚鞐� 鞓來枼鞚� 欷� 靾� 鞛堨姷雼堧嫟.
AEON Biopharma (NYSE: AEON), une entreprise biopharmaceutique en phase clinique d茅veloppant un complexe de toxine botulinique pour plusieurs indications th茅rapeutiques, a annonc茅 sa participation 脿 la 26e Conf茅rence Annuelle Mondiale d'Investissement de H.C. Wainwright 脿 New York, NY. L'茅v茅nement est pr茅vu pour le 11 septembre 2024.
Points cl茅s :
- Marc Forth, Pr茅sident et CEO d'AEON, pr茅sentera un aper莽u de l'entreprise 脿 13h30 ET
- Des r茅unions individuelles avec des investisseurs institutionnels seront disponibles
- Une diffusion en direct de l'茅v茅nement de la conf茅rence sera accessible par l'interm茅diaire de l'h么te de la conf茅rence
Cette participation offre 脿 AEON l'opportunit茅 de mettre en avant ses progr猫s et d'engager des discussions avec des investisseurs potentiels, ce qui pourrait influencer sa position sur le march茅 et ses perspectives de financement futur.
AEON Biopharma (NYSE: AEON), ein biopharmazeutisches Unternehmen in der klinischen Phase, das einen Botulinumtoxin-Komplex f眉r mehrere therapeutische Indikationen entwickelt, hat seine Teilnahme an der 26. j盲hrlichen globalen Investorenkonferenz von H.C. Wainwright in New York, NY, angek眉ndigt. Die Veranstaltung ist f眉r den 11. September 2024 geplant.
Wichtige Punkte:
- Marc Forth, Pr盲sident und CEO von AEON, wird um 13:30 Uhr ET eine Unternehmens眉bersicht pr盲sentieren
- Einzelgespr盲che mit institutionellen Investoren werden verf眉gbar sein
- Ein Live-Stream der Konferenzveranstaltung wird 眉ber den Gastgeber der Konferenz zug盲nglich sein
Diese Teilnahme bietet AEON die M枚glichkeit, seine Fortschritte zu pr盲sentieren und mit potenziellen Investoren in Kontakt zu treten, was potenziell seine Marktposition und zuk眉nftige Finanzierungsm枚glichkeiten beeinflussen k枚nnte.
- None.
- None.
IRVINE, Calif., Aug. 19, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (鈥淎EON鈥� or the 鈥淐ompany鈥�) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the treatment of multiple therapeutic indications, today announced that Marc Forth, AEON鈥檚 President and Chief Executive Officer, will present a corporate overview on Wednesday, September 11, 2024 at 1:30 PM ET at the H.C. Wainwright 26th Annual Global Investment Conference in New York, NY.
Mr. Forth will also participate in one-on-one meetings, and institutional investors interested in meeting during the conference should contact their H.C. Wainwright representative.
A live webcast of the conference event will be available through the conference host.
About AEON Biopharma
AEON is a clinical stage biopharmaceutical company focused on developing its proprietary botulinum toxin complex, ABP-450 (prabotulinumtoxinA) injection, or ABP-450, for debilitating medical conditions, with an initial focus on the neurosciences market. ABP-450 is the same botulinum toxin complex that is currently approved and marketed for cosmetic indications by Evolus under the name Jeuveau. ABP-450 is manufactured by Daewoong in compliance with current Good Manufacturing Practice, or cGMP, in a facility that has been approved by the U.S. Food and Drug Administration, Health Canada and European Medicines Agency. The product is approved as a biosimilar in Mexico and India. AEON has exclusive development and distribution rights for therapeutic indications of ABP-450 in the United States, Canada, the European Union, the United Kingdom, and certain other international territories. The Company has built a highly experienced management team with specific experience in biopharmaceutical and botulinum toxin development and commercialization. To learn more about AEON, visit .
Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements related to participation in and/or presentation at certain investor relations events. AEON undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of AEON in general, see AEON鈥檚 current and future filings with the U.S. Securities and Exchange Commission (the 鈥淪EC鈥�), which are available on the SEC鈥檚 website at www.sec.gov.
Contacts
Investor Contact:
Corey Davis, Ph.D.
LifeSci Advisors
+1 212 915 2577
Source: AEON Biopharma
FAQ
When is AEON Biopharma presenting at the H.C. Wainwright Global Investment Conference?
Who will be presenting for AEON Biopharma at the investment conference?
Will AEON Biopharma be available for one-on-one meetings at the conference?
How can investors access AEON Biopharma's presentation at the conference?
What is the main focus of AEON Biopharma's research?
